NASDAQ:IKT

Inhibikase Therapeutics Stock Insider Trading

Healthcare > Biotechnology

Buy IKT

*Your capital is at risk

$2.18

-0.1000 (-4.39%)

At Close: Jul 31, 2026

Inhibikase Therapeutics Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be positive at 97.85. In total, the insiders bought 54.25M and sold 18.8M IKT shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	97.85
● Buy	54.25M shares
● Sell	18.8M shares
89% Buy Activity Moderate Positive Correlation
Buy Signal High Confidence Jun 26, 2026 Analysis Breakdown: Strongly supported by a very high Insider Power Score of 97.85. Partially supported by a positive historical correlation. Confidence increased due to high data reliability score of 100. Supported by overwhelming buy-side pressure (89% buys).

Historical Insider Trades

Date	Type	Person	Role	Amount
Feb 14, 2025 Buy	Stock Option (Right to Buy) A-Award	Munshi Amit Director	Director	56 600 Value: $133.0K
Feb 14, 2025 Buy	Stock Option (Right to Buy) A-Award	Munshi Amit Director	Director	116 585 Value: $274.0K
Feb 14, 2025 Buy	Stock Option (Right to Buy) A-Award	Freeman Roy Lester Director	Director	22 640 Value: $53.2K
Feb 14, 2025 Buy	Stock Option (Right to Buy) A-Award	Bellini Roberto Director	Director	73 580 Value: $172.9K
Feb 14, 2025 Buy	Stock Option (Right to Buy) A-Award	Bellini Roberto Director	Director	116 585 Value: $274.0K
Feb 14, 2025 Buy	Stock Option (Right to Buy) A-Award	Kush Arvind Director	Director	56 600 Value: $133.0K
Feb 14, 2025 Buy	Stock Option (Right to Buy) A-Award	Kush Arvind Director	Director	116 585 Value: $274.0K
Feb 14, 2025 Buy	Common Stock J-Other	Iwicki Mark T Insider	Other	0 Value: $0
Feb 14, 2025 Buy	Stock Option (Right to Buy) A-Award	Iwicki Mark T Chief Executive Officer	CEO / President	4 373 857 Value: $10.3M
Jan 21, 2025 Buy	Stock Option (Right to Buy) A-Award	Berman Dennis N Director	Director	21 854 Value: $27.5K
Jan 21, 2025 Buy	Stock Option (Right to Buy) A-Award	Freeman Roy Lester Director	Director	1 138 Value: $1K
Jan 21, 2025 Buy	Stock Option (Right to Buy) A-Award	Lees-rolfe Garth Chief Financial Officer	C-Suite Officer	90 000 Value: $113.4K
Jan 21, 2025 Buy	Stock Option (Right to Buy) A-Award	Lees-rolfe Garth Chief Financial Officer	C-Suite Officer	5 834 Value: $7K
Jan 21, 2025 Sell	Stock Option (Right to Buy) D-Return	Lees-rolfe Garth Chief Financial Officer	C-Suite Officer	5 834 Value: $22.1K
Jan 21, 2025 Sell	Stock Option (Right to Buy) D-Return	Lees-rolfe Garth Chief Financial Officer	C-Suite Officer	90 000 Value: $194.4K
Jan 21, 2025 Buy	Stock Option (Right to Buy) A-Award	Freeman Roy Lester Director	Director	30 000 Value: $37.8K
Jan 21, 2025 Buy	Stock Option (Right to Buy) A-Award	Freeman Roy Lester Director	Director	21 854 Value: $27.5K
Jan 21, 2025 Buy	Stock Option (Right to Buy) A-Award	Freeman Roy Lester Director	Director	6 667 Value: $8K
Jan 21, 2025 Buy	Stock Option (Right to Buy) A-Award	Freeman Roy Lester Director	Director	3 780 Value: $5K
Jan 21, 2025 Buy	Stock Option (Right to Buy) A-Award	Freeman Roy Lester Director	Director	1 138 Value: $1K
Jan 21, 2025 Sell	Stock Option (Right to Buy) D-Return	Freeman Roy Lester Director	Director	6 667 Value: $24.1K
Jan 21, 2025 Sell	Stock Option (Right to Buy) D-Return	Freeman Roy Lester Director	Director	30 000 Value: $46.2K
Jan 21, 2025 Sell	Stock Option (Right to Buy) D-Return	Freeman Roy Lester Director	Director	21 854 Value: $730.6K
Jan 21, 2025 Sell	Stock Option (Right to Buy) D-Return	Freeman Roy Lester Director	Director	1 138 Value: $68.3K
Jan 21, 2025 Sell	Stock Option (Right to Buy) D-Return	Freeman Roy Lester Director	Director	3 780 Value: $66.2K

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT INHIBIKASE THERAPEUTICS, INC.

Inhibikase Therapeutics, Inc., a clinical stage pharmaceutical company, develops therapeutics for Parkinson's Disease (PD) and related disorders that arise inside and outside of the brain. The company's product candidates include IkT-148009, a small molecule Abelson tyrosine kinase inhibitor for use in the treatment of PD, as well as gastrointestinal complications that arise as early symptoms of PD, such as swallowing, dysphagia, neurogenic const...

Read Full Profile Here